Loading…
Immuron Ltd Is A Commercial- And Clinical-Stage Biopharmaceutical Company Focused On The Development And Commercialization Of Specifically Targeted Polyclonal Antibodies. Its Oral Polyclonal Antibodies Offer Delivery Within The Gi Tract And Can Target Viruses Or Bacteria And Neutralize Toxins At Mucosal Surfaces. The Company Markets Travelan In Australia, An Over-The-Counter Orally Administered Passive Immunotherapeutic Product Indicated To Reduce The Risk Of Traveler'S Diarrhea And Minor Gastrointestinal Disorders. Its Products Include Travelan, Proibs And Protectyn. Its Segments Are Research And Development And Hyper-Immune Products, With Hyper-Immune Products Generating Maximum Revenue. Australia Generates Maximum Revenue.